Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T76024
|
||||
| Former ID |
TTDC00085
|
||||
| Target Name |
C1 esterase
|
||||
| Gene Name |
C1S
|
||||
| Synonyms |
C1 esterase; C1-esterase; C1S
|
||||
| Target Type |
Successful
|
||||
| Disease | Hereditary angioedema [ICD9: 277.6; ICD10: D84.1] | ||||
| Stroke [ICD9: 434.91, 437.6, 453, 671.5, 671.9; ICD10: I61-I63, I80-I82] | |||||
| Function |
C1s b chain is a serine protease that combineswith c1q and c1s to form c1, the first component of the classical pathway of the complement system. C1r activates c1s so that it can, in turn, activate c2 and c4.
|
||||
| BioChemical Class |
Peptidase
|
||||
| Target Validation |
T76024
|
||||
| UniProt ID | |||||
| EC Number |
EC 3.4.21.42
|
||||
| Sequence |
MWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE
LSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF TGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF TALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF VAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP NSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG IPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK CVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN REPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK MGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV EKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG TYGLYTRVKNYVDWIMKTMQENSTPRED |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Cinryze | Drug Info | Approved | Hereditary angioedema | [1] |
| TS01 | Drug Info | Phase 1 | Stroke | [2] | |
| Modulator | Cinryze | Drug Info | [3] | ||
| TS01 | Drug Info | [4] | |||
| Inhibitor | compound 28 | Drug Info | [5] | ||
| Fucose | Drug Info | [6] | |||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| KEGG Pathway | Complement and coagulation cascades | ||||
| Pertussis | |||||
| Staphylococcus aureus infection | |||||
| Systemic lupus erythematosus | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| WikiPathways | Complement and Coagulation Cascades | ||||
| Complement Activation, Classical Pathway | |||||
| Human Complement System | |||||
| Complement cascade | |||||
| References | |||||
| REF 1 | Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037017) | ||||
| REF 3 | 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. | ||||
| REF 4 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
| REF 5 | A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2200-4. Epub 2006 Feb 3. | ||||
| REF 6 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.